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ABSTRACT
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited cause of end-stage kidney failure.
At present, only one drug, tolvaptan, has been approved for use to slow disease progression, but its use is limited by
reduced tolerability and idiosyncratic liver toxicity. Thiazolidinediones were first developed as insulin-sensitizers but also
regulate gene transcription in multiple tissues, leading to systemic effects on metabolism, inflammation and vascular
reactivity. In this issue, Blazer-Yost et al. report the results of a single-centre Phase 1b double-blind placebo-controlled
crossover study of the peroxisome proliferator-activated receptor c (PPAR-c) agonist pioglitazone in 18 ADPKD patients.
Encouragingly, there were no major safety signals, although evidence of efficacy could not be demonstrated due to the
small sample size. We review the preclinical evidence for the use of PPAR-c agonists in ADPKD and speculate on the likely
beneficial and adverse clinical effects of this interesting class of compounds in a future trial.
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INTRODUCTION
Autosomal dominant polycystic kidney disease (ADPKD) is the
most common inherited cause of end-stage kidney failure [1]. It
has an estimated clinical prevalence of <1 in 2000, although its
genetic prevalence could be higher due to many asymptomatic
undiagnosed cases in the general population [2]. Around 10% of
patients on renal replacement therapy have ADPKD, making it a
disease of considerable personal, societal and economic impact.
At present, only one drug, tolvaptan, has been approved for use
to slow disease progression, but its use is limited by reduced tol-
erability and idiosyncratic liver toxicity [3]. Therefore alterna-
tive drugs (for those intolerant to tolvaptan) and combination
approaches (to reduce its side effects and maximize efficacy)
are urgently needed.
Thiazolidinediones (TZDs) were first developed as insulin
sensitizers to improve glycaemic control in patients with Type 2
diabetes mellitus. They function as agonists of peroxisome pro-
liferator-activated receptor c (PPAR-c), which dimerizes with ret-
inoic acid receptor A to form a co-repressor complex regulating
the transcription of multiple target genes (Figure 1) [4]. The
most widely prescribed TZDs, pioglitazone and rosiglitazone,
have been widely used as second-line agents to control glycae-
mia in diabetic patients. Beyond glycaemic control, anti-protei-
nuric effects have been observed in diabetic nephropathy and
other forms of glomerulonephritis such as immunoglobulin A
nephropathy and focal segmental glomerulosclerosis [4]. More
recently, their use has become more restricted due to an in-
creased incidence of death and heart failure [5, 6]. TZDs block
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both epithelial sodium channel–dependent and –independent
sodium excretion, leading to oedema as a common side effect
of treatment that can in turn exacerbate incipient heart failure
[7, 8].
In this issue, Blazer-Yost et al. report the results of a single-
centre Phase 1b double-blind placebo-controlled crossover
study of the PPAR-c pioglitazone in 18 ADPKD patients
(ClinicalTrials.gov NCT02697617) [9]. A low dose (15mg) of pio-
glitazone or placebo was given for 12months each with a transi-
tion to the opposite arm after a short washout period. The
primary endpoints were to monitor the known side effects of
PPAR-c agonists and included incident episodes of fluid reten-
tion, heart failure, liver toxicity and hypoglycaemia. Secondary
endpoints were to assess changes in total kidney volume (TKV),
blood pressure (BP) and kidney function (estimated glomerular
filtration rate determined with the Chronic Kidney Disease
Epidemiology Collaboration equation).
Fifteen patients (83%) completed the 2-year study with 3
dropouts (17%) due to unspecified personal reasons (two
patients at Months 3 or 12) or pregnancy (one patient at Month
6): all 18 patients were included in the safety analysis.
Encouragingly, there were no major safety signals, i.e. episodes
of heart failure or liver toxicity. Unexpectedly, total body water
as assessed by bioimpedance analysis was significantly reduced
during pioglitazone treatment. One patient had asymptomatic
recurrent episodes of unexplained non-fasting hypoglycaemia
(<4mmol/L).
Unfortunately, the secondary endpoints were not met due
to a smaller sample size than anticipated. The authors had cal-
culated that a minimum of 22 recruits to complete both arms
were required to demonstrate a treatment effect of 33% with
pioglitazone on an estimated annual TKV growth of 6%.
Despite ‘aggressive recruitment’, this was not achieved, thus
rendering the study underpowered for efficacy. Nonetheless,
pioglitazone was associated with a trend towards a reduced
rate of TKV growth compared with placebo (4.366.3% versus
7.856 7.68%; P¼ 0.15). A greater decrease in TKV (3.5%) was
detected, although a higher rate of annual TKV growth (8%)
was present in this cohort compared with previous studies
(6%): all study participants fell within a rapid disease progres-
sion classification (Mayo Imaging Class 1C–E). Similarly, a non-
significant reduction in diastolic BP was detected with pioglita-
zone (83 versus 86mmHg; P¼ 0.08), consistent with previous
non-ADPKD trials [10]. The authors did not test higher doses of
pioglitazone due to concerns about likely dose-dependent side
effects and after extrapolation from their preclinical data sug-
gested maximal efficacy from a low dose in rodent models
(Table 1).
In conclusion, low-dose pioglitazone (15mg) was found to
be safe when given to a small cohort of ADPKD patients with
early but rapidly progressive disease over 12months. The risk
of hypoglycaemia appeared to be mitigated at this dose, al-
though exposure to a larger population with a wider range of
age and kidney function could yet unmask a higher incident
rate. The lack of increased oedema and heart failure was reas-
suring given concerns regarding cardiac safety signals
unmasked in clinical trials of PPAR-c agonists in diabetic
patients [6].
The lack of efficacy on the main exploratory outcome of an-
nual TKV growth was likely related to an insufficient sample
size, although the additional possibility that a suboptimal dose
was used cannot be excluded. The authors designed their study
based on data suggesting that a lower dose of pioglitazone was
more effective than a higher dose in rodent PKD models, argu-
ing that the basis for this is a specific effect on cystic fibrosis
transmembrane conductance regulator(CFTR) messenger RNA
FIGURE 1: (A) TZDs activate PPARc–retinoid X receptor functional heterodimers, which in turn regulate gene transcription (PPAR response elements) in multiple tissues,
resulting in widespread effects on metabolism, osteogenesis, proteinuria, vascular reactivity and inflammation as reviewed by Mao and Ong [4]. (B) Single-cell Pparg
gene expression in mouse adult kidney showing predominant expression in the vasculature and immune cells with detectable low tubular expression in specific seg-
ments, i.e. S3 proximal tubule and inner medullary collecting duct (average expression <0.04). The numbered segments correspond to the segmentation reported in
the Kidney Cell Explorer (Ontology identification 1–32) [11].
















































































[19]. Despite this premise, it is apparent that a consistent effect
of PPAR-c agonists has not been found in all PKD rodent models
tested so far, including orthologous ones (Table 1). In addition,
both pleiotropic systemic and renal effects of these compounds
beyond CFTR are likely given the widespread tissue and limited
nephron expression of PPAR-c (Figure 1).
The stage is now set for a Phase 2 parallel-arm multicentre
trial of pioglitazone in ADPKD. With no options to slow disease
progression in the last 150years, new treatment possibilities for
ADPKD are now rapidly emerging, including drug-repurposing
approaches [20, 21]: PPAR-c agonists could yet find a new lease
on life in the treatment of ADPKD.
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(Y/N/NA) Adverse events Extrarenal effects
Muto
et al. [12]
Pioglitazone (80) Pkd1 null (M, F) E 7.5 (2days) NA NA None Improved survival;
decreased oedema,
cardiac defects






PN 1 (20weeks) N Y (1 M) None Improved survival;
increased BW












PCK rat (M, F) Week 3 (7weeks) Y (M) at 7weeks
both doses
NA None Decreased fractional
liver weights at low
dose
Pioglitazone (20) PCK rat (F) Week 4
(14weeks)




Pioglitazone (10) PCK rat (M, F) Week 4
(16weeks)
















Wpk rat (M, F) PN 5 (14days) Y (0.2mg/kg
group only)










N NA None NA
M, male; F, female; Y, yes; N, no; NA, not assessed; EDD, endothelium-dependent dilatation; BW, body weight; E, embryonic; PN, post-natal.
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